These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 37919088)

  • 1. Modulation of Alpha-Synuclein Conformational Ensemble and Aggregation Pathways by Dopamine and Related Molecules.
    Natalello A; Brocca S; Ponzini E; Santambrogio C; Grandori R
    Front Biosci (Landmark Ed); 2023 Oct; 28(10):266. PubMed ID: 37919088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural Features and Toxicity of α-Synuclein Oligomers Grown in the Presence of DOPAC.
    Palazzi L; Fongaro B; Leri M; Acquasaliente L; Stefani M; Bucciantini M; Polverino de Laureto P
    Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34199427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aldehyde dehydrogenase 1 defines and protects a nigrostriatal dopaminergic neuron subpopulation.
    Liu G; Yu J; Ding J; Xie C; Sun L; Rudenko I; Zheng W; Sastry N; Luo J; Rudow G; Troncoso JC; Cai H
    J Clin Invest; 2014 Jul; 124(7):3032-46. PubMed ID: 24865427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alpha-synuclein/synapsin III pathological interplay boosts the motor response to methylphenidate.
    Faustini G; Longhena F; Bruno A; Bono F; Grigoletto J; La Via L; Barbon A; Casiraghi A; Straniero V; Valoti E; Costantino G; Benfenati F; Missale C; Pizzi M; Spillantini MG; Bellucci A
    Neurobiol Dis; 2020 May; 138():104789. PubMed ID: 32032728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the intrinsically disordered structural ensemble of α-synuclein by small molecules as a potential therapeutic strategy for Parkinson's disease.
    Tóth G; Gardai SJ; Zago W; Bertoncini CW; Cremades N; Roy SL; Tambe MA; Rochet JC; Galvagnion C; Skibinski G; Finkbeiner S; Bova M; Regnstrom K; Chiou SS; Johnston J; Callaway K; Anderson JP; Jobling MF; Buell AK; Yednock TA; Knowles TP; Vendruscolo M; Christodoulou J; Dobson CM; Schenk D; McConlogue L
    PLoS One; 2014; 9(2):e87133. PubMed ID: 24551051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoamine oxidase and α-synuclein as targets in Parkinson's disease therapy.
    Follmer C
    Expert Rev Neurother; 2014 Jun; 14(6):703-16. PubMed ID: 24852232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthetic alpha-synuclein fibrils cause mitochondrial impairment and selective dopamine neurodegeneration in part via iNOS-mediated nitric oxide production.
    Tapias V; Hu X; Luk KC; Sanders LH; Lee VM; Greenamyre JT
    Cell Mol Life Sci; 2017 Aug; 74(15):2851-2874. PubMed ID: 28534083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alpha-Synuclein transgenic mice, h-α-SynL62, display α-Syn aggregation and a dopaminergic phenotype reminiscent of Parkinson's disease.
    Frahm S; Melis V; Horsley D; Rickard JE; Riedel G; Fadda P; Scherma M; Harrington CR; Wischik CM; Theuring F; Schwab K
    Behav Brain Res; 2018 Feb; 339():153-168. PubMed ID: 29180135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Research Progress of α-Synuclein Aggregation Inhibitors for Potential Parkinson's Disease Treatment.
    Kalsoom I; Wang Y; Li B; Wen H
    Mini Rev Med Chem; 2023; 23(20):1959-1974. PubMed ID: 37198991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fasudil Promotes α-Synuclein Clearance in an AAV-Mediated α-Synuclein Rat Model of Parkinson's Disease by Autophagy Activation.
    Yang YJ; Bu LL; Shen C; Ge JJ; He SJ; Yu HL; Tang YL; Jue Z; Sun YM; Yu WB; Zuo CT; Wu JJ; Wang J; Liu FT
    J Parkinsons Dis; 2020; 10(3):969-979. PubMed ID: 32568105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iron, Dopamine, and α-Synuclein Interactions in at-Risk Dopaminergic Neurons in Parkinson's Disease.
    Song N; Xie J
    Neurosci Bull; 2018 Apr; 34(2):382-384. PubMed ID: 29380248
    [No Abstract]   [Full Text] [Related]  

  • 12. Modulation of alpha-synuclein aggregation by dopamine: a review.
    Leong SL; Cappai R; Barnham KJ; Pham CL
    Neurochem Res; 2009 Oct; 34(10):1838-46. PubMed ID: 19444607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intracerebral Administration of a Ligand-ASO Conjugate Selectively Reduces α-Synuclein Accumulation in Monoamine Neurons of Double Mutant Human A30P*A53T*α-Synuclein Transgenic Mice.
    Pavia-Collado R; Cóppola-Segovia V; Miquel-Rio L; Alarcón-Aris D; Rodríguez-Aller R; Torres-López M; Paz V; Ruiz-Bronchal E; Campa L; Artigas F; Montefeltro A; Revilla R; Bortolozzi A
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33805843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Age-dependent nigral dopaminergic neurodegeneration and α-synuclein accumulation in RGS6-deficient mice.
    Luo Z; Ahlers-Dannen KE; Spicer MM; Yang J; Alberico S; Stevens HE; Narayanan NS; Fisher RA
    JCI Insight; 2019 May; 5(13):. PubMed ID: 31120439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adenosine A1 receptor ligands bind to α-synuclein: implications for α-synuclein misfolding and α-synucleinopathy in Parkinson's disease.
    Jakova E; Moutaoufik MT; Lee JS; Babu M; Cayabyab FS
    Transl Neurodegener; 2022 Feb; 11(1):9. PubMed ID: 35139916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interactions of dopamine, iron, and alpha-synuclein linked to dopaminergic neuron vulnerability in Parkinson's disease and Neurodegeneration with Brain Iron Accumulation disorders.
    Wise RM; Wagener A; Fietzek UM; Klopstock T; Mosharov EV; Zucca FA; Sulzer D; Zecca L; Burbulla LF
    Neurobiol Dis; 2022 Dec; 175():105920. PubMed ID: 36351559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction of alpha-synuclein and dopamine metabolites in the pathogenesis of Parkinson's disease: a case for the selective vulnerability of the substantia nigra.
    Galvin JE
    Acta Neuropathol; 2006 Aug; 112(2):115-26. PubMed ID: 16791599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The deglycase activity of DJ-1 mitigates α-synuclein glycation and aggregation in dopaminergic cells: Role of oxidative stress mediated downregulation of DJ-1 in Parkinson's disease.
    Sharma N; Rao SP; Kalivendi SV
    Free Radic Biol Med; 2019 May; 135():28-37. PubMed ID: 30796974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modelling α-Synuclein Aggregation and Neurodegeneration with Fibril Seeds in Primary Cultures of Mouse Dopaminergic Neurons.
    Tourville A; Akbar D; Corti O; Prehn JHM; Melki R; Hunot S; Michel PP
    Cells; 2022 May; 11(10):. PubMed ID: 35626675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review on the interactions between dopamine metabolites and α-Synuclein in causing Parkinson's disease.
    Sivakumar P; Nagashanmugam KB; Priyatharshni S; Lavanya R; Prabhu N; Ponnusamy S
    Neurochem Int; 2023 Jan; 162():105461. PubMed ID: 36460239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.